Wrap Text
Transactions by persons discharging managerial responsibilities
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")
21 July 2021
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out details of the vesting and settlement of awards over ordinary shares in the
Company granted on 19 June 2019 in respect of the deferred element of the short-term incentive (“STI”)
scheme pay-out for the financial year ended 31 March 2019. These awards were due to vest on 19 June
2021; however, in view of the potential development of sensitive information at the time relating to
Ramsay Health Care’s now expired offer for Spire, the Committee judged it prudent to defer vesting
until 20 July 2021.
The awards were granted under the Company’s previous remuneration policy, approved by
shareholders in July 2017. Accordingly, they will be settled in cash on 27 July 2021, based on the
middle-market quotation of a share on 19 July 2021, being 282.2 pence per share. The amount settled
includes the value of dividends attributable to the vested shares during the period between the date of
grant and the date of vesting, being a total of 7.90 pence per share.
The table below sets out the number of shares vested for the directors who were granted awards under
the STI on 19 June 2019, together with the corresponding cash settlement.
Name Number of shares vested Cash settlement
(including dividend
equivalents)
Dr Carel Aron van der Merwe1 21 962 £63 712
Petrus Jurgens Myburgh1 14 417 £41 824
Daniël Petrus Meintjes2 7 679 £22 277
Note:
1. As Executive Directors, Dr Ronnie van der Merwe and Jurgens Myburgh are required to build up
and maintain a minimum holding of shares equivalent to a value of 225% and 200% of their annual
base compensation respectively. As the holding requirements have not been met, under the
Company’s Remuneration Policy, Ronnie van der Merwe and Jurgens Myburgh are each required
to use 50% of the net of tax proceeds to purchase ordinary shares in Mediclinic.
2. As explained on page 171 of the 2019 Annual Report, upon Danie Meintjes’ retirement as an
executive Director on 31 July 2018, the Remuneration Committee considered both investors’
expectations and South African labour market requirements in determining the treatment of his
outstanding incentive awards. In accordance with his Service Agreement and the shareholder-
approved Directors’ Remuneration Policy, it was agreed that Danie Meintjes remained eligible to
receive a pro-rated STI award in June 2019 in respect of the period during which he served as an
executive Director (1 April 2018 to 31 July 2018).
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Chief Executive Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in FY19 under the
Company’s short-term incentive scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 21 962
d) Aggregated
information
Aggregated volume 21 962
Price £nil
e) Date of the 20 July 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Chief Financial Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in FY19 under the
Company’s short-term incentive scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 14 417
d) Aggregated
information
Aggregated volume 14 417
Price £nil
e) Date of the 20 July 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Non-executive director of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in FY19 under the
Company’s short-term incentive scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 7 679
d) Aggregated
information
Aggregated volume 7 679
Price £nil
e) Date of the 20 July 2021
transaction
f) Place of the Outside a trading venue
transaction
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates ("UAE").
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.
At 1 July 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case
clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The Company’s primary listing is on the LSE in the UK, with secondary listings on the JSE in South
Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 21-07-2021 11:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
